IP Library Granted Patent US 9,084,815
Granted Patent B2
US 9,084,815 · App. 12/882,794 · Granted Jul 21, 2015

Method for treating damage induced by an anti-tumor agent, treating mucositis and treating tumor

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,084,815
App. No.
12/882,794
Granted
Jul 21, 2015
Kind
B2
Abstract

Disclosed is a method for treating tumor in a mammalian subject, which comprises administering a combination of (a) an anti-tumor agent and (b) a fatty acid derivative represented by the formula (I): to the subject in need thereof. The application also discloses a method for treating damages, especially gastrointestinal damages including mucositis such as stomatitis induced by an anti-tumor agent, wherein the method comprises administering a fatty acid derivative of formula (I) to the subject who is receiving the anti-tumor agent.

Claims (6)

1. A method for treating oral mucositis induced by an anti-tumor agent in a mammalian subject, which comprises administering a pharmaceutically effective amount of (−)-7-{(2R,4aR,5R,7aR)-2-[(3S)-1,1-difluoro-3-methylpentyl]-2-hydroxy-6-oxooctahydrocyclopenta[b]pyran-5-yl}heptanoic acid to the subject in need thereof, wherein the subject is receiving the anti-tumor agent that is selected from the group consisting of an alkylating agent, an antimetabolite, an antibiotic, a plant alkaloid, a molecular targeting drug, a hormone, a platinum complex, an antisense, an antibody and RNAi,

wherein the molecular targeting drug is selected from the group consisting of imatinib, gefinitib, erlotinib, sorafenib, sunitinib, trastuzumab, rituximab, gemtuzumab-ozogamicin, bevacizumab and cetuximab, the hormone is selected from group consisting of prednisolone, diethylstilbestrol and tamoxifen, the antisense is selected from the group consisting of bcl-2 antisense, hsp27 antisense, XIAP antisense, PKC-alpha antisense and hypoxia-induced factor antisense, the antibody is selected from the group consisting of CD20 antibody, Her2 antibody, VEGF antibody and EGFR antibody, and the RNAi is RNAi targeted Ribonucleotide reductase.

2. The method as described in claim 1 , wherein said anti-tumor agent is 5-FU or tegafur.

3. The method as described in claim 1 , wherein said anti-tumor agent is cisplatin.

4. The method as described in claim 1 , wherein the oral mucositis is stomatitis.

5. The method as described in claim 1 , wherein the anti-tumor agent is selected from the group consisting of an alkylating agent, an antimetabolite, an antibiotic and a plant alkaloid.

Assignments (7)
RELEASE OF SECURITY INTEREST Recorded Aug 14, 2025
From: ACQUIOM AGENCY SERVICES LLC
To: SPECGX LLC; MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; OCERA THERAPEUTICS LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC
Reel/Frame 072324/0740 →
RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 060434, FRAME 0536 Recorded Nov 16, 2023
From: DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT
To: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; SPECGX LLC; OCERA THERAPEUTICS, INC.; STRATATECH CORPORATION; VTESSE LLC; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; SUCAMPO PHARMA AMERICAS LLC
Reel/Frame 065601/0347 →
RELEASE OF SECURITY INTERESTS IN PATENTS AT REEL 060389/FRAME 0913 Recorded Nov 15, 2023
From: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT
To: OCERA THERAPEUTICS LLC (F/K/A OCERA THERAPEUTICS, INC.); MALLINCKRODT LLC; MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY; SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED
Reel/Frame 065583/0465 →
SECURITY INTEREST Recorded Nov 15, 2023
From: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; OCERA THERAPEUTICS LLC; SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC
To: ACQUIOM AGENCY SERVICES LLC
Reel/Frame 065595/0376 →
NOTICE OF GRANT OF SECURITY INTEREST IN INTELLECTUAL PROPERTY Recorded Jun 22, 2022
From: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; SPECGX LLC; OCERA THERAPEUTICS, INC.; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY
To: DEUTSCHE BANK AG NEW YORK BRANCH
Reel/Frame 060434/0536 →
SECURITY INTEREST Recorded Jun 17, 2022
From: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; SPECGX LLC; OCERA THERAPEUTICS, INC.; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED
To: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT
Reel/Frame 060389/0913 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 29, 2010
From: UENO, RYUJI
To: SUCAMPO AG
Reel/Frame 025428/0822 →